Allergic rhinitis in adults
Conditions
Interventions
treatment group :sublingual administration
Sponsors
Beijing Tongren Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: (1) Aged between 18 and 60 (including 18 and 60), male or female; (2) have a history of seasonal (summer and autumn) allergic rhinitis, with or without allergic conjunctivitis; (3) The average daily score of four rhinitis symptoms in the last pollen season peak reached 6 or more points; (4) The sIgE level of artemisia was =3, and the sIgE level of ragweed and humulus scandens was lower than artemisia (5) The subject can understand and sign the informed consent; (6) Subjects can comply with the protocol.
Exclusion criteria
Exclusion criteria: (1) Patients with ulcer, inflammation or trauma in the sublingual area during screening evaluation are not suitable for administration; (2) patients who undergo major surgery within four weeks prior to screening evaluation; (3) continuous use of systemic glucocorticoids within 4 weeks prior to screening evaluation; (4) Patients with any history of severe systemic allergic reaction or eosinophilic esophagitis before screening evaluation; (5) patients with perennial allergic rhinitis; (6) patients with chronic rhinitis or sinusitis or nasal polyps; (7) The subjects reviewed the last pollen season, and the onset of rhinitis could be alleviated without using symptomatic drugs; (8) Those who had been diagnosed with moderate or severe asthma or had evidence of FEV1 < 70% of the estimated value within 2 years before enrollment; (9) those who are taking ß -blockers (including systemic and local drugs) or angiotensin converting enzyme (ACE) inhibitors; (10) Those who have participated in clinical trials of other drugs within one month; (11) those receiving other pollen allergen-specific immunotherapy; (12) pregnant and lactating women; (13) Have a history of immunosuppressive diseases (such as HIV infection), malignant tumors, autoimmune diseases, tuberculosis, cardiovascular insufficiency or other serious diseases of organ systems as judged by the investigator; (14) Any other circumstances that the Investigator deems inappropriate for participation in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| daily average combined scores of rhinitis symptoms and medication in pollen peak period; | — |
Secondary
| Measure | Time frame |
|---|---|
| daily average total rhinitis symptom score in pollen peak period;daily average medication score in pollen peak period; | — |
Countries
China
Contacts
Public ContactZhang Luo
Beijing Tongren Hospital
Outcome results
None listed